Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,851.50    31.00 (1.70%)
Bid:
1,851.50
Ask:
1,852.00
Spread: 0.50 (0.027%)
Market Cap: £74.25b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

13 May 2025 15:30

RNS Number : 5056I
GSK PLC
13 May 2025
 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Emma Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

9 (partnership shares)

£13.5075

9 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

18 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Julie Brown

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

10 (partnership shares)

£13.5075

10 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

20 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

10 (partnership shares)

£13.5075

10 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

20 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

9 (partnership shares)

£13.5075

9 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

18 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President, Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

10 (partnership shares)

£13.5075

10 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

20 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

9 (partnership shares)

£13.5075

9 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

18 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Philip Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

9 (partnership shares)

£13.5075

9 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

18 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, Global Health, GSK

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

9 (partnership shares)

£13.5075

9 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

18 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Victoria Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

9 (partnership shares)

£13.5075

9 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

18 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFIFDDEISEII
Date   Source Headline
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20263:30 pmRNSDirector/PDMR Shareholding
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:05 amRNSLinerixibat accepted for priority review in China
26th Feb 20267:00 amRNSBepirovirsen accepted for Japan regulatory review
26th Feb 20267:00 amRNSTransaction in Own Shares
25th Feb 20264:54 pmRNSDirector/PDMR Shareholding
25th Feb 20263:30 pmRNSDirector/PDMR Shareholding
25th Feb 20267:00 amRNSGSK enters agreement to acquire 35Pharma
25th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20263:30 pmRNSDirector/PDMR Shareholding
24th Feb 20267:00 amRNSTransaction in Own Shares
23rd Feb 20267:00 amRNSTransaction in Own Shares
20th Feb 20263:30 pmRNSDirector/PDMR Shareholding
20th Feb 20267:00 amRNSTransaction in Own Shares
19th Feb 20263:30 pmRNSDirector/PDMR Shareholding
19th Feb 20267:00 amRNSTransaction in Own Shares
18th Feb 20267:00 amRNSTransaction in Own Shares
17th Feb 20263:30 pmRNSDirector/PDMR Shareholding
17th Feb 20263:30 pmRNSDirector/PDMR Shareholding
17th Feb 20267:00 amRNSGSK - fourth tranche of share buyback programme
17th Feb 20267:00 amRNSExdensur approved by the European Commission
16th Feb 20263:30 pmRNSDirector/PDMR Shareholding
16th Feb 20263:30 pmRNSDirector/PDMR Shareholding
16th Feb 20263:30 pmRNSDirector/PDMR Shareholding
11th Feb 20263:30 pmRNSDirector/PDMR Shareholding
11th Feb 20263:30 pmRNSDirector/PDMR Shareholding
11th Feb 20263:30 pmRNSDirector/PDMR Shareholding
11th Feb 20263:30 pmRNSDirector/PDMR Shareholding
10th Feb 20267:00 amRNSChina CDE accepts Arexvy adults 60+ application
9th Feb 20263:30 pmRNSDirector/PDMR Shareholding
6th Feb 202610:30 amRNSDirector/PDMR Shareholding
6th Feb 20267:00 amRNSNucala COPD approved by the European Commission
5th Feb 20263:30 pmRNSDirector/PDMR Shareholding
4th Feb 20267:00 amRNSFinal Results
2nd Feb 20263:00 pmRNSTotal Voting Rights
26th Jan 20267:00 amRNSEuropean Commission approves Arexvy for adults 18+
20th Jan 20267:05 amRNSGSK to acquire RAPT Therapeutics
20th Jan 20267:00 amRNSAgreement on changes to ViiV minority shareholding
16th Jan 20263:30 pmRNSDirector/PDMR Shareholding
15th Jan 20263:30 pmRNSDirector/PDMR Shareholding
13th Jan 20263:30 pmRNSDirector/PDMR Shareholding
7th Jan 20267:05 amRNSEC approval of Shingrix PFS
7th Jan 20267:00 amRNSPositive phase 3 data for GSK's bepirovirsen
6th Jan 20267:00 amRNSExdensur approved in Japan
5th Jan 20263:30 pmRNSDirector/PDMR Shareholding
5th Jan 20263:00 pmRNSTotal Voting Rights
5th Jan 20267:00 amRNSNucala for adults with COPD approved in China
22nd Dec 20253:30 pmRNSDirector/PDMR Shareholding
22nd Dec 20253:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.